Parkinsonism: FDG Metabolic Patterns¹⁸F-FDG · ¹²³I-ioflupane

Quick Answer

A DaTscan (¹²³I-ioflupane) answers one question — is there presynaptic nigrostriatal dopaminergic loss (parkinsonism) or not (essential tremor, drug-induced, psychogenic)? — but it cannot distinguish Parkinson disease from the "Parkinson-plus" syndromes, because they all lose dopaminergic terminals. That subtyping is where brain FDG-PET earns its place: each disorder has a characteristic regional metabolic signature. Idiopathic Parkinson disease (IPD) shows a specific spatial-covariance pattern (PDRP: relatively increased pallidum/thalamus and pons with cortical decreases) and relatively preserved striatal metabolism; multiple system atrophy (MSA) shows putaminal (MSA-P) or cerebellar/pontine (MSA-C) hypometabolism; progressive supranuclear palsy (PSP) shows midbrain and medial-frontal hypometabolism; corticobasal degeneration (CBD) shows asymmetric fronto-parietal and basal-ganglia hypometabolism; and dementia with Lewy bodies (DLB) shows occipital hypometabolism with the cingulate island sign (relative sparing of the posterior cingulate). Used together, DAT imaging confirms parkinsonism and FDG subtypes it.

Why DaTscan can't subtype

¹²³I-ioflupane binds the presynaptic dopamine transporter; an abnormal scan means nigrostriatal degeneration, distinguishing degenerative parkinsonism from non-dopaminergic mimics (essential tremor, drug-induced, vascular, psychogenic). But IPD, MSA, PSP, and CBD all share presynaptic dopaminergic loss, so DaTscan is typically abnormal in all of them and cannot say which. FDG metabolism, by contrast, reflects downstream network dysfunction that differs by disease — which is what allows subtyping.

The metabolic signatures

The patterns to recognize:

The cingulate island sign — relative sparing of the posterior cingulate against reduced precuneus/cuneus — helps separate DLB from Alzheimer disease (where the posterior cingulate is typically involved). Spatial-covariance analysis (PDRP and disease-specific patterns) can quantify these signatures beyond visual reading.

Putting it together

In practice, the two tracers are complementary: order DAT-SPECT to confirm that a clinical parkinsonism is truly neurodegenerative, and add FDG-PET when the question is which parkinsonian syndrome — because prognosis and counseling differ sharply between IPD and the more aggressive atypical syndromes. Cardiac ¹²³I-MIBG (reduced in Lewy-body disease) and structural MRI (e.g. midbrain atrophy in PSP) add further discriminators. The unifying idea: transporter imaging localizes the lesion; metabolic imaging reveals the network fingerprint.

High-Yield Pearls

• DaTscan confirms dopaminergic parkinsonism but is abnormal in IPD, MSA, PSP, and CBD alike — it can't subtype.
• FDG-PET subtypes: PSP → midbrain/medial-frontal, MSA-P → putamen, MSA-C → cerebellum/pons, CBD → asymmetric fronto-parietal, IPD → PDRP with preserved striatum.
• DLB → occipital hypometabolism + cingulate island sign, which helps separate it from Alzheimer disease.
• The tracers are complementary: DAT for is it neurodegenerative parkinsonism, FDG for which one.

Common Pitfalls

• Expecting DaTscan to distinguish PD from Parkinson-plus — it cannot.
• Missing the cingulate island sign and calling DLB "Alzheimer."
• Over-reading subtle asymmetry without correlating the clinically worse side (CBD).

Related Pages

• Tracers/related: I-123-Ioflupane (DaTscan), Brain FDG & dementia imaging, Amyloid & tau PET; selection: Dementia & movement-disorder imaging — which test when.

Differential Diagnosis

• Normal/borderline DAT points away from a degenerative parkinsonism toward essential tremor, drug-induced or psychogenic parkinsonism, and dopa-responsive dystonia (the "scans without evidence of dopaminergic deficit" group).
• Vascular parkinsonism — lower-body predominant, with white-matter/lacunar disease on MRI and a variable or patchy DAT.
• DLB vs Alzheimer disease — both show posterior hypometabolism, but occipital involvement + the cingulate island sign favor DLB.
• MSA-C vs other cerebellar ataxias — the cerebellar/pontine metabolic pattern overlaps with spinocerebellar and other degenerative ataxias; correlate clinically.
• Drug-induced parkinsonism superimposed on early PD — dopamine-blocker exposure can coexist with a truly abnormal DAT, complicating attribution.

Reporting Checklist

• State the tracer and the question answered: DAT-SPECT for presence of a presynaptic dopaminergic deficit; FDG-PET for the regional metabolic pattern/subtype.
• For DAT: describe putaminal vs caudate reduction, symmetry/laterality, and background — and state that it confirms but does not subtype parkinsonism.
• For FDG: name the pattern (e.g. midbrain/medial-frontal for PSP, putaminal for MSA-P, occipital + cingulate island for DLB) and the syndrome it favors.
• Correlate imaging asymmetry with the clinically worse side (relevant for CBD).
• Suggest complementary tests where indicated (cardiac ¹²³I-MIBG, structural MRI) and integrate findings clinically rather than diagnosing from imaging alone.

Self-Check

Key References

• EANM/SNMMI guidelines on ¹²³I-FP-CIT (DaTscan) and brain FDG-PET in movement disorders.
• Spatial-covariance-pattern literature (PDRP and disease-related patterns) for differentiating parkinsonian syndromes.